The Dutch government has widened its national security screening rules to cover foreign investments in artificial intelligence and biotechnology. The move, announced in recent weeks, gives authorities more power to block or impose conditions on deals they deem risky. It's part of a broader European trend toward tighter oversight of strategic technologies.
What the new rules cover
The expanded regime now applies to any foreign acquisition of or investment in Dutch companies working on AI and biotech. Previously the screening focused only on sectors like energy, telecoms, and defense. The government has not specified exact thresholds or deal sizes that will trigger a review, but it said the aim is to protect sensitive knowledge and dual-use technologies — those with both civilian and military applications.
Potential chill on foreign money
Investors and tech firms in the Netherlands worry the new checks could scare off international capital. The country has long been a magnet for foreign venture funding, especially in AI startups and biotech research clusters around Utrecht and Leiden. A slower, less predictable approval process could push some deals elsewhere. That's a real risk for companies that rely on cross-border partnerships to fund early-stage development.
Innovation and collaboration under question
The screening rules don't just affect money — they also touch how Dutch researchers and companies work with foreign partners. Tightened controls could hamper joint projects, data sharing, and talent exchanges. Researchers in biotech often collaborate across borders; AI development relies on global open-source communities and shared computing resources. The government says it will weigh benefits case by case, but critics argue the uncertainty itself can chill collaboration. No one wants to start a partnership that might later be unwound by a security review.
How the Netherlands balances openness with security is the open question. The government has not yet released guidance on how it will assess AI or biotech deals, nor any timeline for decisions. Until those details come, investors and researchers are left watching from the sidelines.
